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==========================

*Chryseobacterium indologenes* is a known colonizer of inanimate objects in the hospital environment.\[[@ref1]\] *C. indologenes* is not a part of human microflora, but it has been increasingly isolated from patients with bacteremia, pneumonia, and artificial shunt infections, especially in those who are admitted with long-term indwelling devices and prolonged exposure to broad-spectrum antibiotics.\[[@ref2][@ref3][@ref4][@ref5][@ref6]\] Opportunistic infections due to this organism, often arising from colonization of indwelling mechanical devices, are on the rise.\[[@ref3]\] It has increasingly been reported from Southeast Asia, mainly from Taiwan.\[[@ref6]\] However, there is a paucity of data regarding its occurrence and associated risk factors in the Indian healthcare set ups. The present study was aimed to quantify the burden of *C. indologenes* infections among the patients admitted in different disciplines.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Consecutive specimens of blood, respiratory secretions, and urine received between February 15 and August 15, 2016, in the bacteriology laboratory of our hospital, were evaluated for the presence of *Chryseobacterium* spp. on routine culture. Blood specimens were cultured in BACTEC plus aerobic and anaerobic bottles (BD Diagnostics, Sparks, MD) followed by subculture on blood agar and MacConkey agar plates. Respiratory specimens (endotracheal aspirate, sputum, bronchial washing, and bronchoalveolar lavage fluid) were cultured onto blood, MacConkey, and hemin agar plates, incubated overnight at 37°C. Urine specimens were cultured on blood agar and CHROMagar (HiChrome, HiMedia, Mumbai, India) plates using semiquantitative calibrated loop technique.

Provisional identification of *Chryseobacterium* spp was made if yellow-colored, oxidase-positive colony of Gram-negative bacilli with unusual susceptibility pattern of resistance to carbapenems and colistin but susceptibility to vancomycin was observed.

Such isolates were further subjected to an automated method for identification and antibiotic susceptibility testing by BD Phoenix™ automated system (BD Diagnostic Systems, Sparks, MD). Results of antibiotic susceptibility testing were interpreted as per the Clinical and Laboratory Standards Institute guidelines 2016.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 12 isolates (six from blood, two from endotracheal aspirates and four from urine) met the criteria of provisional identification of *Chryseobacterium* spp. All these isolates were confirmed as *C. indologenes* by BD Phoenix™ automated system. These isolates were recovered from 11 patients; in one patient, *C. indologenes* was isolated from blood and endotracheal aspirate who had both septicemia and ventilation-associated pneumonia (VAP).

The age of patients ranged from 17 months to 80 years with mean age of 54.23 ± 25.39 years. The antibiotic susceptibility profile of the isolates showed that 91.67% were sensitive to trimethoprim-sulfamethoxazole, followed by 75% to levofloxacin, 41.67% to ciprofloxacin, and 16.67% to piperacillin + tazobactam. All the isolates were resistant to cefotaxime, ceftazidime, cefepime, aztreonam, gentamicin, amikacin, chloramphenicol, imipenem, meropenem, and colistin \[[Table 1](#T1){ref-type="table"}\].

###### 

Minimum inhibitory concentration of *Chryseobacterium indologenes* (*n*=12) as determined by BD Phoenix™ automated system
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The comorbidities associated with individual patients such as diabetes, hypertension, history of stroke, coronary artery disease, end-stage renal disease, recent surgery (within the last 30 days), and history of VAP during the course of current admission are shown in [Table 2](#T2){ref-type="table"}. All patients had at least one mechanical device inserted (central venous catheter, ventilator, or urinary catheter) at the time of diagnosis of *C. indologenes* infection. The average time duration between hospital admission and diagnosis of *C. indologenes* infection was 15.27 ± 12.18 days, and the mortality was 25% \[[Table 2](#T2){ref-type="table"}\].

###### 

Summary of comorbidities, risk factors, mechanical device use, and outcome of patients with *Chryseobacterium indologenes* infections of different sites
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Antibiotic use during the current admission showed that almost all patients were prescribed at least one of fluoroquinolones, third-generation cephalosporins, carbapenems, and colistin. Concurrent steroid use was in 83.33% of cases \[[Table 3](#T3){ref-type="table"}\].

###### 

Exposure to drugs during 7 days prior to isolation of *Chryseobacterium indologenes*
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D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The provisional identification of *C. indologenes* isolates is based on their yellow pigmentation and positive potassium hydroxide test, coupled with an unusual antimicrobial pattern, i.e., resistance to carbapenems and colistin, while being susceptible to vancomycin.

The isolation of an uncommon organism from clinical sample naturally sparks a debate about the clinical significance of the isolate. All the isolates of *C. indologenes* from bloodstream infection (BSI) were from febrile patients and were considered true pathogens.\[[@ref7]\] Both isolates of *C. indologenes* from endotracheal aspirates of patients on mechanical ventilation were considered to cause VAP as determined by clinical assessment.

The two *C. indologenes* isolates were cultured from urine obtained from percutaneous nephrostomy catheters of two patients on three consecutive days. Both patients presented with fever and were treated with levofloxacin without catheter removal. Both patients responded clinically within 48 h, and their subsequent urine cultures were sterile. Such a presentation indicates a true infection of the percutaneous nephrostomy site, as reported previously from India.\[[@ref8]\]

Most cases were admitted to postoperative wards (three urology, two pulmonary, two surgical gastroenterology, and two neurosurgery) followed by two cases from critical care units and one from the nephrology Intensive Care Unit. The average number of days between patient admission and the first detection of *C. indologenes* was around 20 days; hence, all were categorized under nosocomial infections/colonizations. All the 11 patients had at least one mechanical device (central line, ventilator, and Foley\'s catheter), suggesting the acquisition of *C. indologenes* through such mechanical devices.

The SENTRY study is the only study to have estimated the epidemiology and antimicrobial susceptibility profile of *C. indologenes* infections worldwide.\[[@ref1]\] It analyzed the profile of 50 *Chryseobacterium* isolates recovered from 119 sentinel sites covering the Americas, Europe, and the Asia-Pacific region from 1997 to 2001. The study documents 12 cases from a single center in India, over a mere 6-month period. The SENTRY study found *C. meningosepticum* (now *Elizabethkingia meningosepticum*) to outnumber *C. indologenes* as the most common species isolated (24 vs. 20 strains), whereas *C. indologenes* was the only species identified in our study.

The isolates in SENTRY were more susceptible to levofloxacin (98%) than to trimethoprim + sulphamethoxazole (87.8%) and ciprofloxacin (80%). The isolates from Asia-Pacific region were relatively more resistant to piperacillin-tazobactam than those from North America (50% vs. 100%), while susceptible toward levofloxacin was comparable (100% vs. 98%). Our isolates were highly susceptible to trimethoprim + sulfamethoxazole (91.67%), followed by levofloxacin (75%). Only 16.67% and 41.67% isolates in the present study were susceptibility to piperacillin-tazobactam and ciprofloxacin compared to 80% and 80%, respectively, in the SENTRY study. These findings suggest that the Indian isolates of *C. indologenes* differ from the rest of the world, and the antimicrobial susceptibility pattern obtained from the rest of the Asia-Pacific region cannot be generalized to India. Taiwan is the country from which maximum strains of *Chryseobacterium* have been reported in the world. Despite its geographical proximity to India, there is a remarkable difference in the characterization of clinical isolates. Chen *et al*. in their study reported a staggering 215 *Chryseobacterium* isolates over a 7½-year study from a single center.\[[@ref6]\] In that study, the isolation rate of *Chryseobacterium* from patients with pneumonia was much higher than from BSIs (91 vs. 22 cases).

The risk factor profile of individual cases had some similarities. Both studies found hypertension, diabetes, stroke, and ventilator use to be the most common risk factors. The high rate of malignancy and chronic kidney disease as underlying factors reported by Chen *et al*. was negligible among our patient population.\[[@ref6]\] A significant observation was that three-fourths of our patients developed *C. indologenes* infection following surgical interventions. This might be an important risk factor among our patients, which should be explored in future studies.

There has been some debate over the need to remove indwelling mechanical devices during therapy. In most of our cases, the device was not removed, and therapy was started promptly, and the recovery rate was 75%. Other studies have also reported similar successful outcome without catheter removal.\[[@ref2][@ref5]\]

To conclude, *C. indologenes* should be recognized as an emerging nosocomial pathogen, especially among patients admitted to postoperative and critical care units. Its association with indwelling catheters and devices is well established, but devices need not be removed while administering appropriate therapy. Our cases have additionally shown recent surgical intervention to be a possible risk factor. The organism has a peculiar susceptibility to trimethoprim + sulfamethoxazole and levofloxacin while being resistant to other commonly used antimicrobial agents for Gram-negative infections, such as carbapenems and colistin. Microbiology laboratories should provisionally identify and perform susceptibility testing for this organism to help clinicians decide effective therapeutic options.
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